Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotech 2006—the numbers

Nature Biotechnology volume 25, pages 729–737 (2007)Cite this article

Although biotech revenue and R&D spending continued to expand rapidly last year, profitability became a little more elusive.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Public biotech company revenue, R&D spending, profits and number of employees by market cap.
Figure 2: Global biotech industry financing.
Figure 3: Global biotech IPOs.
Figure 4: Public biotech companies by geographical location.

Author information

Authors and Affiliations

  1. Data retrieval for this article was by Riku Lähteenmäki, a freelance writer in Turku, Finland, and Stacy Lawrence, BioCentury senior writer. Stacy Lawrence provided the analysis.,

    Riku Lähteenmäki & Stacy Lawrence

Authors
  1. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stacy Lawrence
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lähteenmäki, R., Lawrence, S. Public biotech 2006—the numbers. Nat Biotechnol 25, 729–737 (2007). https://doi.org/10.1038/nbt0707-729

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0707-729

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing